Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentino Conter

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Pediatric Reports|October 28, 2025
A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision MedicineMaurizio Aricò, Valentino Conter
Haematologica|July 1, 2021
Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?Valentino Conter, Francesco Ceppi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2023
Optimizing Pediatric Leukemia Care in Countries With Limited ResourcesRaul C Ribeiro, Valentino Conter
Blood|December 14, 2023
Closing the circle for ETP ALLElaine Coustan-Smith, Valentino Conter
Cancer|February 24, 2022
Does the Y chromosome play a role for outcome in childhood acute lymphoblastic leukemia?Valentino Conter, Martin Schrappe, Gabriele Escherich
JCO Global Oncology|January 15, 2026
Childhood ALL in Low- and Middle-Income Countries: Achievements and ChallengesAnjo J P Veerman, Valentino Conter
Haematologica|March 20, 2025
Does allopurinol enhance efficacy of acute lymphoblastic leukemia maintenance therapy?Kjeld Schmiegelow, Linea Natalie Toksvang, Valentino Conter
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission: where are we now?Adriana Balduzzi, Valentino Conter, Cornelio Uderzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Importance of minimal residual disease testing during the second year of disease: still no answer?Maurizio Aricò, Valentino Conter, Maria Grazia Valsecchi, et al.
Expert Review of Hematology|August 10, 2021
Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemiaFrancesco Ceppi, Frida Rizzati, Antonella Colombini, et al.
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Pediatric Reports|October 28, 2025
A Decade of Transformation in the Management of Childhood Acute Lymphoblastic Leukemia: From Conventional Chemotherapy to Precision MedicineMaurizio Aricò, Valentino Conter
Haematologica|July 1, 2021
Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?Valentino Conter, Francesco Ceppi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2023
Optimizing Pediatric Leukemia Care in Countries With Limited ResourcesRaul C Ribeiro, Valentino Conter
Blood|December 14, 2023
Closing the circle for ETP ALLElaine Coustan-Smith, Valentino Conter
Cancer|February 24, 2022
Does the Y chromosome play a role for outcome in childhood acute lymphoblastic leukemia?Valentino Conter, Martin Schrappe, Gabriele Escherich
JCO Global Oncology|January 15, 2026
Childhood ALL in Low- and Middle-Income Countries: Achievements and ChallengesAnjo J P Veerman, Valentino Conter
Haematologica|March 20, 2025
Does allopurinol enhance efficacy of acute lymphoblastic leukemia maintenance therapy?Kjeld Schmiegelow, Linea Natalie Toksvang, Valentino Conter
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission: where are we now?Adriana Balduzzi, Valentino Conter, Cornelio Uderzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Importance of minimal residual disease testing during the second year of disease: still no answer?Maurizio Aricò, Valentino Conter, Maria Grazia Valsecchi, et al.
Expert Review of Hematology|August 10, 2021
Utilizing the prognostic impact of minimal residual disease in treatment decisions for pediatric acute lymphoblastic leukemiaFrancesco Ceppi, Frida Rizzati, Antonella Colombini, et al.
Pageof 14